Inflammatory mediators in macrophages

Macrophages are central players in the innate immune system, acting as primary producers of various inflammatory mediators in response to pathogens or tissue damage (Source: Nature Reviews Immunology, "Macrophages in inflammation", 2017). These mediators include pro-inflammatory cytokines such as Tumor Necrosis Factor-alpha, Interleukin-1 beta, and Interleukin-6, as well as chemokines and lipid-derived signaling molecules like prostaglandins (Source: StatPearls, "Innate Immunity", 2023). While these substances are essential for initiating an effective immune response and promoting tissue repair, their dysregulation or chronic overproduction is a hallmark of numerous inflammatory and autoimmune diseases (Source: NIH, "Inflammation", 2022). Therapeutic strategies often focus on specific mediators within this group, employing monoclonal antibodies to neutralize cytokines or small molecules to inhibit the enzymes responsible for their synthesis (Source: PubChem, "Infliximab"). Because this term encompasses a broad array of distinct molecular entities rather than a single receptor or enzyme, it serves as a functional category in immunology rather than a specific discrete drug target (Source: UniProt, "Cytokine").

Other names

Macrophage-derived inflammatory factorsPro-inflammatory mediatorsMacrophage cytokinesInflammatory secretome of macrophagesMacrophage inflammatory mediators

Drugs targeting these mediators typically act by neutralizing secreted proteins (monoclonal antibodies), blocking their respective receptors (antagonists), or inhibiting the intracellular enzymes and signaling pathways (e.g., JAK/STAT, NF-kappaB) required for their production and action.